Skip to main content

Sensex, Nifty rally 7% in July; more than 100 stocks in BSE500 rose 10-80%

Although broader market indices i.e. the S&P BSE Small-cap index and the S&P BSE Mid-cap index closed with gains of over 5 percent each but more than 100 stocks in the BSE500 index rallied 10-80% in July.

 

Bulls pushed benchmark indices above their crucial resistance levels in July but profit-taking in the last week of July capped the upside. The S&P BSE Sensex and Nifty50 rallied over 7 percent each in July but the real action was in select mid & small-cap space.

Although broader market indices i.e. the S&P BSE Small-cap index and the S&P BSE Mid-cap index closed with gains of over 5 percent each but more than 100 stocks in the BSE500 index rallied 10-80% in July.

There are as many as 126 stocks in the S&P BSE 500 index which rallied 10-80% in the month of July that include names like Cadila Healthcare, PVR, Bank of Maharashtra, M&M, Dr Lal Pathlabs, Heritage Foods, L&T Infotech, and Laurus Labs, etc. among others.

Experts are of the view that due to underperformance in the broader market space, smart buying is happening in select quality stocks. However, the right approach would be to enter this space in a staggered way rather than making a lump sum payment.

“Most frontline stocks may have risen excessively portraying high valuations but select mid and small caps are certainly not trading at high multiples, they are decently priced some even undervalued,” Umesh Mehta, Head of Research, Samco Group told Moneycontrol.

“Hence, selective buying in certain pockets of the broader markets can entice investors in their search for value. A staggered buying strategy through SIPs in fundamentally strong small and mid-cap stocks is the right approach, especially when they are trading at decent valuations but buying lump sum at current is not advisable,” he said.


 


 

Technical Outlook:

Weakness in the heavyweights like Reliance Industries and HDFC twins drove the headline index – Nifty50 lower. The Nifty50 formed a bullish candle on the monthly charts; however, some profit-taking was seen in the last week of July.

Overall, Nifty seems to be consolidating sideways in a range as it has entered the GAP zone which was created due to the massive selloff witnessed in the March early this year.

Experts are of the view that on the upside 11300-11400 levels are likely to act as stiff resistance while on the downside 11000-11040 will act as a crucial support zone.

“On the upside 11300-11400 is the supply zone which also happens to be the upper end of the GAP area and on the downside 11040 is the demand zone. Any significant move will be witnessed on a breakout from this trading range,” Aditya Agarwala, Senior Technical Analyst - Institutional Equities, YES SECURITIES told Moneycontrol.

“Following two strong expires from the point of view of bulls, the Nifty could take a pause and may witness minor profit booking while broader markets may continue to rise,” he said.

Agarwala further added that the Nifty is facing resistance at the 78.6% retracement placed at 11400 which also happens to be the GAP area, failure to break out of this resistance may invite bears to push the Index lower to 10800. Therefore, Nifty in Aug series may trade with mild weakness.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions (and same applies to sd solutions as well)

Source - Moneycontrol.com

 



Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more